Cadila Healthcare slumps amid reports that US FDA raised concerns

Written by fe Bureau | Mumbai | Updated: Jul 31 2014, 19:56pm hrs
Shares of Cadila Healthcare slipped more than 10% intraday on Thursday on reports that the US Food and Drug Administration (FDA) has raised concerns over the manufacturing process of at least one product at Cadila's Moraiya facility.

As per the Reuters report, the US FDA had not raised concerns over the entire facility.

The Cadila Healthcare Ltd scrip was trading 4.54% lower at Rs 1112.55 on the BSE at 1.40 pm IST.